The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
825
August 24, 1990
View Complete Issue         Table of Contents 2019 
Nafarelin For Endometriosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nafarelin For Endometriosis
August 24, 1990 (Issue: 825)
Nafarelin acetate (Synarel - Syntex), a synthetic analog of gonadotropin-releasing hormone (GnRH), was recently approved by the US Food and Drug Administration for treatment of endometriosis. The drug is available only in a nasal spray...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nafarelin For Endometriosis
Article code: 825b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.